Emergent BioSolutions (EBS) has secured a $51.9M contract modification award to deliver CNJ-016 to the Administration for Strategic Preparedness and Response (A ...

About an hour after the closing bell, shares of Emergent were trading 6.4% higher, at $7.31. The company's shares ended the day's regular session at $6.87, a gain of 3.7%.

Emergent BioSolutions shares rose after the company disclosed that it will supply additional doses of CNJ-016, a treatment ...

Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification has been secured to deliver CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) to the Administration for ...

Investing.com -- Emergent BioSolutions Inc (NYSE: EBS) stock rose 6.3% after the company announced a contract modification to deliver additional doses of its smallpox vaccination complication ...

South Korea has developed the world's first recombinant protein-based anthrax vaccine, a major step toward self-sufficiency ...

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency by the WHO.

Find the latest Emergent BioSolutions Inc. (EBS) stock quote, history, news and other vital information to help you with your stock trading and investing.

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.